NEW YORK, Aug. 28, 2018 /PRNewswire/ -- Neurotrope, Inc.
(NASDAQ: NTRP), a clinical-stage biopharmaceutical company
developing novel therapies for neurodegenerative diseases,
including Alzheimer's disease (AD), today announced it will be
featured as a presenting company at the 20th Annual
Rodman & Renshaw Global Investment Conference, sponsored by
H.C. Wainwright & Co., LLC. The conference is being held
on September 4-6, 2018 at the St. Regis New York Hotel in
New York City.
The Company has also been selected to present at the prestigious
25th Annual NewsMakers in the Biotech Industry on
Friday, September 7th, 8:30am Eastern Time, at the Millennium Broadway
Hotel and Conference Center in New York. This presentation
will not be available for webcast.
Drs. Charles Ryan, and
Daniel Alkon, Neurotrope's CEO and
President / CSO, will provide an overview of the Company's business
plan and technology during their live presentations and they will
also be available to participate in one-on-one meetings throughout
the days with investors who are registered to attend the
conferences.
Neurotrope is currently conducting a
Confirmatory Phase 2 clinical trial using its lead drug
Bryostatin-1, in patients with moderate to severe AD. The
therapeutic target of Bryostatin-1 is PKC
epsilon. Regeneration of new synaptic networks by
PKC epsilon's coordination of synaptic growth factors such as BDNF,
NGF and IGF is believed to be responsible for the improvement of
patients' cognitive function, recently observed in Neurotrope's
Exploratory Phase 2 trial for moderate to severe Alzheimer's
patients. These improvements in patients Severe Impairment
Battery (SIB) scores were observed, even 30 days after completion
of all dosing. Activation of PKC epsilon also
activates enzymes such as IDE, ECE and neprilysin. The
function of those enzymes are known to degrade A Beta
oligomers. PKC epsilon activation also inhibits GSK3beta,
which inhibits the production of hyperphosphorylated
tau. These multi-modal effects caused by PKC epsilon
activation are performed through the activation of innate enzymes
in the brain, as opposed to the delivery of monoclonal antibodies
currently being utilized by most of the sponsors conducting AD
clinical trials.
If you are an institutional investor, and would like to attend
the Company's presentation, please click on the following link
(www.rodmanevents.com) to register for the conference. Once
your registration is confirmed, you will be prompted to log into
the conference website to request a one-on-one meeting with the
Company.
Event: 20th Annual Rodman
& Renshaw Global Investment Conference, sponsored by H.C.
Wainwright & Co., LLC
Date: September 6th, 2018
Time: 4:40 – 5:05 PM (Eastern
Time)
Location: Maisonnette Lower Level; St. Regis New York
Hotel
A live webcast of presentation at the Rodman conference will be available on the
Company website in the investors and media section under events and
presentations. The presentation will also be archived on the
Company's website and be available for replay.
Below is a link to the webcast:
http://wsw.com/webcast/rrshq28/ntrp/
About Neurotrope
Neurotrope is at the forefront of developing a new approach to
combating AD and other neurodegenerative diseases. The
Company's world-class science offers the potential to realize a
paradigm shift to overcome one of today's most challenging clinical
problems — finding a way to slow or even prevent the progression of
AD.
In addition to the Company's Phase 2 trial of Bryostatin-1 in
advanced AD, Neurotrope has also conducted preclinical studies of
bryostatin as a potential treatment for Stroke, Traumatic Brain
Injury, and Fragile X Syndrome, Niemann-Pick Type C disease and
Rett Syndrome—rare genetic diseases for which only symptomatic
treatments are currently available. The FDA has granted Orphan Drug
Designation to Neurotrope for Bryostatin-1 as a treatment for
Fragile X Syndrome. Bryostatin-1 has already undergone testing
in more than 1,500 people in cancer studies, thus creating a large
safety data base that will further inform clinical trial designs in
AD.
Please visit www.neurotrope.com for further
information.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 study and further studies, and continued
development of use of Bryostatin-1 for Alzheimer's dementia and
other cognitive diseases. Such forward-looking statements are
subject to risks and uncertainties and other influences, many of
which the Company has no control over. These statements are subject
to the risk that further analyses of the Phase 2 data may lead to
different interpretations of the data than the analyses conducted
to date and/or may identify important implications of the Phase 2
data that are not reflected in these statements. Clinical trial
data are subject to differing interpretations, and regulatory
agencies, medical and scientific experts and others may not share
the Company's views of the Phase 2 data. There can be no assurance
that the clinical program for Bryostatin-1 will be successful in
demonstrating safety and/or efficacy that we will not encounter
problems or delays in clinical development, or that Bryostatin-1
will ever receive regulatory approval or be successfully
commercialized. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Additional factors that may influence or cause
actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand the Company's business,
significant government regulation of pharmaceuticals and the
healthcare industry, lack of product diversification, availability
of the Company's raw materials, existing or increased
competition, stock volatility and illiquidity, and the
Company's failure to implement the Company's business plans or
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including the
Company's Annual Report on Form 10-K for the year
ended December 31, 2017, and on Form 10-Q for the quarter
ended June 30, 2018. The Company does
not undertake to update these forward-looking statements.
Contact information:
Investors and Media
Jeffrey Benison, Director of Corporate Communications
Neurotrope, Inc.
516.286.6099 (C) or 212.334.8709 (O)
View original
content:http://www.prnewswire.com/news-releases/neurotrope-announces-participation-at-the-20th-annual-rodman--renshaw-global-investment-conference-in-new-york-city-september-4-6-2018-300703044.html
SOURCE Neurotrope, Inc.